Unbound MEDLINE

Oral treatment with Hev b 13 ameliorates experimental colitis in mice.

Abstract

Hev b 13 is an allergenic esterase obtained from the rubber tree Hevea brasiliensis, which has been shown recently to induce human mononuclear cells to release interleukin (IL)-10 in vitro. This immunoregulatory cytokine appears to play an important role in preventing inflammation and mucosal damage in animal models of colitis and in Crohn's disease patients. The aim of this study was to evaluate the therapeutic effect of Hev b 13 in mice with 2,4,6-trinitrobenzene sulphonic acid (TNBS)-induced colitis. Two hours following colonic instillation of the haptenizing agent, and daily thereafter for 5 days, Hev b 13 was administered by oral gavage. In mice treated with daily doses of either 0·5 mg/kg or 5·0 mg/kg of Hev b 13, the clinical signs of diarrhoea, rectal prolapse and body weight loss and also histological damage of the distal colon, were reduced significantly, in comparison with water-treated diseased mice. These findings suggest a potent anti-inflammatory activity of Hev b 13; this activity is speculated to be related to its interaction with cells from the immune system.

Links

  • Aggregator Full Text
  • Authors

    Teixeira LB, Epifânio VL, Lachat JJ, Foss NT, Coutinho-Netto J

    Institution

    Department of Biochemistry and Immunology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, Brazil. larissadbt@usp.br

    Source

    Clinical and experimental immunology 169:1 2012 Jul pg 27-32

    MeSH

    Administration, Oral
    Animals
    Anti-Inflammatory Agents, Non-Steroidal
    Antigens, Plant
    Colitis
    Colon
    Crohn Disease
    Diarrhea
    Female
    Humans
    Interleukin-10
    Mice
    Mice, Inbred BALB C
    Plant Proteins
    Rectal Prolapse
    Trinitrobenzenesulfonic Acid
    Weight Loss

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    22670775